Hauser, S. L., Cross, A. H., Winthrop, K., Wiendl, H., Nicholas, J., Meuth, S. G., . . . Kappos, L. (2022). Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years. Multiple sclerosis, 28(10), 1576. https://doi.org/10.1177/13524585221079731
Citace podle Chicago (17th ed.)Hauser, Stephen L., et al. "Safety Experience with Continued Exposure to Ofatumumab in Patients with Relapsing Forms of Multiple Sclerosis for Up to 3.5 years." Multiple Sclerosis 28, no. 10 (2022): 1576. https://doi.org/10.1177/13524585221079731.
Citace podle MLA (9th ed.)Hauser, Stephen L., et al. "Safety Experience with Continued Exposure to Ofatumumab in Patients with Relapsing Forms of Multiple Sclerosis for Up to 3.5 years." Multiple Sclerosis, vol. 28, no. 10, 2022, p. 1576, https://doi.org/10.1177/13524585221079731.